ALNY - דינמיקת הכנסות משנה לשנה ב-12 החודשים האחרונים Alnylam Corp

Alnylam Pharmaceuticals (ALNY) seeks to solidify its leadership in RNA interference by expanding into the treatment of mass pathologies. The rolling annual sales growth rate reflects revenue dynamics, where the indicator value reaches 56.20. The implementation of robotic oligonucleotide synthesis is accelerating the development of new therapies. Financial stability is supported by licensing deals and joint gene therapy research with global behemoths.
alnylam.com (ALNY) - פילוחי מדדים ודוחות פיננסיים

This indicator reflects operational efficiency by smoothing quarterly volatility through the calculation of rolling year-over-year revenue growth to identify true market momentum. For Alnylam Pharmaceuticals (ALNY), this methodology enables the tracking of the transition from a narrow orphan drug niche to the mass cardiology market, as clearly demonstrated by the rolling year-over-year commercial revenue dynamics.